DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 95 filers reported holding DYNE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $7,990,433 | +19.6% | 226,422 | -3.8% | 0.00% | 0.0% |
Q1 2024 | $6,679,827 | +245.2% | 235,288 | +61.7% | 0.00% | – |
Q4 2023 | $1,934,804 | +86.3% | 145,474 | +25.5% | 0.00% | – |
Q3 2023 | $1,038,778 | -16.5% | 115,935 | +4.9% | 0.00% | – |
Q2 2023 | $1,243,845 | +41.7% | 110,564 | +45.1% | 0.00% | – |
Q1 2023 | $878,043 | -2.9% | 76,219 | -2.3% | 0.00% | – |
Q4 2022 | $904,484 | -13.5% | 78,040 | -5.3% | 0.00% | – |
Q3 2022 | $1,046,000 | +60.2% | 82,420 | -13.3% | 0.00% | – |
Q2 2022 | $653,000 | -28.8% | 95,113 | 0.0% | 0.00% | – |
Q1 2022 | $917,000 | -95.6% | 95,113 | -94.6% | 0.00% | -100.0% |
Q4 2021 | $20,963,000 | -48.3% | 1,763,053 | -29.3% | 0.00% | -57.1% |
Q3 2021 | $40,524,000 | -51.9% | 2,495,387 | -37.7% | 0.01% | -50.0% |
Q2 2021 | $84,317,000 | +43.2% | 4,007,432 | +5.7% | 0.01% | +40.0% |
Q1 2021 | $58,871,000 | -2.4% | 3,790,777 | +30.5% | 0.01% | -9.1% |
Q4 2020 | $60,315,000 | +21.0% | 2,904,722 | +14.2% | 0.01% | +10.0% |
Q3 2020 | $49,861,000 | – | 2,542,760 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vida Ventures Advisors, LLC | 2,960,046 | $35,195,000 | 13.16% |
MPM ASSET MANAGEMENT LLC | 4,951,303 | $58,871,000 | 12.72% |
Atlas Venture Life Science Advisors, LLC | 8,934,902 | $106,236,000 | 9.76% |
Logos Global Management LP | 3,234,392 | $38,457,000 | 3.97% |
GREAT POINT PARTNERS LLC | 845,000 | $10,047,000 | 2.23% |
Deep Track Capital, LP | 2,292,250 | $27,255,000 | 1.92% |
Octagon Capital Advisors LP | 583,649 | $6,940,000 | 1.35% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 476,000 | $5,641,000 | 1.26% |
COMMODORE CAPITAL LP | 305,125 | $3,628,000 | 0.84% |
RA Capital Management | 2,805,045 | $33,352,000 | 0.59% |